'RISE' Clinician Scientist Programme
The RISE programme (Rare Important Syndromes in Endocrinology) supports clinically working researchers in the CRC/TRR 205.
In 2020, six young clinical research fellows from the universities of Dresden, Munich and Würzburg joined the RISE Clinician Scientist Programme, which offers a unique opportunity to combine basic or clinical research activities with in-depth clinical training in paediatric or adult endocrinology. The fellows collaborated closely across the three sites and produced outstanding scientific results, published in 27 original articles and 15 scientific reviews.
As part of the programme, the fellows participated in a comprehensive scientific and clinical training programme in endocrinology. They are each supported by three mentors who guide them in their scientific and clinical careers. The fellows will soon complete their board examinations in paediatrics or internal medicine and complete their habilitation thesis. They will then pursue academic careers in paediatric or adult endocrinology.
By presenting our RISE concept and results from the first funding period to the Eva Luise und Horst Köhler Foundation and the Else Kröner-Fresenius Foundation, we were able to convince the reviewers to grant us a second funding period with a grant of €1.2 million for a period of three years. This extension of the RISE programme gives us the opportunity to attract more talented young fellows to join the programme and benefit from a total of 18 months of protected research time.
The close connection with the Collaborative Research Centre TRR 205 provides an optimal research environment for basic science and clinical endocrinology, which enables the intensification of research work and the start of a successful career as a clinician scientist. The aim is to improve applied and patient-oriented medical research.
The Research College focuses on diseases of the hypothalamus-pituitary-adrenal (HPA) axis, also known as the stress axis. These diseases are rare and their symptoms are usually non-specific and insidious. This makes early diagnosis and targeted treatment difficult. The consequences are irreversible organ damage and, in rare cases, even life-threatening metabolic disorders. The aim of the funding programme is to train clinician-scientists who can improve the care of patients with diseases of the HPA axis.
Funding period:
- 36 months (2020 – 2022) (first funding period)
- 36 months (2020 – 2022) (second funding period)
Funding scope: 6 Clinician Scientists – two at each of the University hospitals in Dresden, Munich and Würzburg
Spokesperson
Prof Dr Angela Hübner, TU Dresden
Co-speaker
Prof Dr Nicole Reisch (LMU Munich),
Prof Dr Martin Fassnacht (JMU Würzburg)
RISE Coordinator
PD Dr rer. nat. Katrin Köhler, TU Dresden